Ultragenyx Pharmaceutical Reports Q3 2026 Earnings Miss on EPS and Revenue
Ultragenyx Pharmaceutical (RARE) reported third-quarter financial results for the period ending September 30, 2026, missing both top and bottom-line analyst expectations. The company posted a GAAP earnings per share (EPS) of -$1.16, falling $0.14 short of estimates, while revenue reached $173 million, missing consensus by $10.71 million. Despite the miss, the company saw an 8.1% year-over-year increase in revenue. As of the end of the quarter, Ultragenyx maintained a strong liquidity position with $401 million held in cash, cash equivalents, and marketable securities.
Tickers: $RARE
Topics: cash flow earnings miss financial results revenue miss
Read the full article at Seeking Alpha
Part of the story Waste Management Q3 Earnings Analysis: Strong Free Cash Flow Offsets EPS Miss (4 articles)